Biotech Startups Bet AI’s Biggest Win Isn’t Drug Discovery
Part of composite article AI Is About to Run the Whole Damn Lab — and Anthropic Just Bet $400 Million on It View full article →
A new wave of biotech startups is questioning whether drug discovery is the best use of artificial intelligence. In this edition of AI Prognosis, these companies argue that AI’s largest impact may lie elsewhere in the industry.